U.S., June 10 -- ClinicalTrials.gov registry received information related to the study (NCT07637448) titled 'EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC' on May 28.
Brief Summary: This study is an open-label, multicenter, single-arm clinical study.
Study Start Date: May 21
Study Type: INTERVENTIONAL
Condition:
Lung Cancer Non-Small Cell Cancer (NSCLC)
EGFR Activating Mutation
PD-1 Antibody
Intervention:
DRUG: EGFR-TKIs Combined with PD-1 Monoclonal Antibody
EGFR-TKIs Combined with PD-1 Monoclonal Antibody
Recruitment Status: RECRUITING
Sponsor: Nanfang Hospital, Southern Medical University
Published by HT Digital Content Services with permission from Health Daily Digest....